Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPEPPS | P55786 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CPA3 | P15088 | 1/20 | 0.62 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Thiorphan SCHEMBL7312756 | 1.00 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| Thiorphan SCHEMBL401174 | 1.00 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| Thiorphan SCHEMBL399227 | 0.92 | MME (0.84) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL8861649 | 0.91 | MME (0.83) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10447979 | 0.90 | MME (0.81) | MMEACEALDH1A1HPGDMAPK1 | |
| Thiorphan SCHEMBL10038977 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL4442570 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10038979 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL8861684 | 0.87 | MME (0.77) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7103054 | 0.85 | MME (0.74) | MMEACEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3924 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739291-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| WO-2026041906-A1 | SEMI-SOLID PHARMACEUTICAL COMPOSITION MICRO-DISPENSER | Azura Ophthalmics Ltd. (IL) | 2026-02-26 | — | — | WO | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025012701-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | claimed |
| US-20240123033-A1 | THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics By Design, LLC (US) | 2024-04-18 | — | — | US | claimed |
| EP-4308587-A1 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics by Design, LLC (US) | 2024-01-24 | — | — | EP | claimed |
| EP-4308103-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | AI Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | claimed |
| EP-0533084-A1 | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation | SCHERING CORPORATION (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0509442-A1 | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | SCHERING CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| WO-1992013564-A1 | COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR | SCHERING CORPORATION (US) | 1992-08-20 | — | — | WO | claimed |
| EP-0498361-A2 | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor | SCHERING CORPORATION (US) | 1992-08-12 | — | — | EP | claimed |
| US-5084007-A | Method for chemical promotion of the effects of low current transcranial electrostimulation | MALIN DAVID H (US) | 1992-01-28 | — | — | US | claimed |
| EP-0415693-A1 | Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence | ARIZONA TECHNOLOGY DEVELOPMENT CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| WO-1991001756-A1 | METHOD FOR CHEMICAL PROMOTION OF THE EFFECTS OF LOW CURRENT TRANSCRANIAL ELECTROSTIMULATION | SKOLNICK MALCOLM H (US) | 1991-02-21 | — | — | WO | claimed |
| US-4740499-A | ADMINISTERING WITH THIORPHAN OR KELATORPHAN | MONSANTO COMPANY (US) | 1988-04-26 | — | — | US | claimed |
| US-4513009-A | GLYCINE, ALANINE AND SERINE DERIVATIVES | SOCIETE CIVILE BIOPROJET (FR) | 1985-04-23 | — | — | US | claimed |